COLL vs EXEL: fair value comparison
Collegium Pharmaceutical, Inc. and Exelixis, Inc. · Updated 2026-09-06
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, COLL currently sits closer to the top of our discount ranking. EXEL carries the stronger quality grade.
| COLL | EXEL | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $35.58 | $55.06 |
| 12-month range | $31.78–$47.11 | $38.06–$55.06 |
| Sector rank | #44 of 113 Healthcare | #46 of 113 Healthcare |
| Quality grade | C- | A |
| Leverage | High | Low |
| Margin trend | — | Stable |
| Revenue growth | — | Strong |
| RSI zone | Oversold | Neutral |
| 50/200-day trend | Mixed | Uptrend |
| DCF cross-check | — | Fairly Valued |
| 52-week position | The bottom quarter | The top quarter |
Full single-stock breakdowns: COLL fair value analysis · EXEL fair value analysis